Renalytix AI (GB:RENX) has released an update.
Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Renalytix AI, an AI-enabled diagnostics firm specializing in kidney disease, reported a total revenue of $2.3 million for FY24, with losses before tax totaling $44.9 million due to significant impairment and fair value adjustments. The company’s total assets stood at $7.3 million, including $4.7 million in cash, by the end of June 2024. Investors are anticipated to see differences between US GAAP and IFRS audited results, specifically in the treatment of intangibles.
For further insights into GB:RENX stock, check out TipRanks’ Stock Analysis page.